Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference. Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference Post navigation Previous: Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)Next: Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates
